Cargando…
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
BACKGROUND: Better biomarkers must be found to develop clinically useful urine tests for bladder cancer. Proteomics can be used to identify the proteins released by cancer cell lines and generate candidate markers for developing such tests. METHODS: We used shotgun proteomics to identify proteins re...
Autores principales: | Bryan, R T, Regan, H L, Pirrie, S J, Devall, A J, Cheng, K K, Zeegers, M P, James, N D, Knowles, M A, Ward, D G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366887/ https://www.ncbi.nlm.nih.gov/pubmed/25719831 http://dx.doi.org/10.1038/bjc.2015.21 |
Ejemplares similares
-
Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential
por: Bryan, R T, et al.
Publicado: (2014) -
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification
por: Snell, Kym I.E., et al.
Publicado: (2018) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer
por: van der Gun, B T F, et al.
Publicado: (2013) -
EpCAM tumor specificity and proteoform patterns in urothelial cancer
por: Dressler, Franz F., et al.
Publicado: (2023)